Literature DB >> 6285697

Endocytosis of lysosomal alpha-galactosidase A by cultured fibroblasts from patients with Fabry disease.

J S Mayes, E L Cray, V A Dell, J B Scheerer, R N Sifers.   

Abstract

The endocytosis of alpha-galactosidase A was studied in cultured fibroblasts from patients with Fabry disease. Alpha-galactosidase A was purified from human placenta by chromatography on concanavalin A-Sepharose, DEAE-cellulose, and N-epsilon-aminocaproyl-alpha-D-galactosylamine-Sepharose. Separation of the high-uptake form of the enzyme from the low-uptake form was accomplished by chromatography on ECTEOLA-cellulose. With the high-uptake form of the enzyme, the uptake was linear at low concentrations of enzyme and had a Kuptake of 0.01 U/ml of medium that corresponds to a Km of 5.0 x 10(-9) M. At high concentrations of enzyme, it became saturated. The high-uptake form could be converted to the low-uptake form by treatment with acid phosphatase. Mannose-6-P strongly inhibited the active uptake of the enzyme. Once taken up into the lysosomes of Fabry disease fibroblasts, alpha-galactosidase A activity was rapidly lost in the first 2 days of incubation at 37 degrees C, but was fairly stable for the next 6 days. The half-life of internalized alpha-galactosidase A activity was calculated to be 4 days. Crosslinking of the enzyme with hexamethylene diisocyanate did not increase the intracellular stability of alpha-galactosidase A activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285697      PMCID: PMC1685365     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  20 in total

1.  Phosphatases: applications of new methods for their separation.

Authors:  P D Dean; S R Willetts; J E Blanch
Journal:  Anal Biochem       Date:  1971-06       Impact factor: 3.365

2.  Isolation of alpha-galactosidase by affinity chromatography.

Authors:  N Harpaz; H M Flowers
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

3.  Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease.

Authors:  R O Brady; J F Tallman; W G Johnson; A E Gal; W R Leahy; J M Quirk; A S Dekaban
Journal:  N Engl J Med       Date:  1973-07-05       Impact factor: 91.245

4.  Correction of the enzymic defect in cultured fibroblasts from patients with Fabry's disease: treatment with purified alpha-galactosidase from ficin.

Authors:  G Dawson; R Matalon; Y T Li
Journal:  Pediatr Res       Date:  1973-08       Impact factor: 3.756

5.  Enzyme therapy. II. Purified human alpha-galactosidase A. Stabilization to heat and protease degradation by complexing with antibody and by chemical modification.

Authors:  P D Snyder; F Wold; R W Bernlohr; C Dullum; R J Desnick; W Krivit; R M Condie
Journal:  Biochim Biophys Acta       Date:  1974-06-18

6.  Fabry's disease: absence of an -galactosidase isozyme.

Authors:  S Wood; H L Nadler
Journal:  Am J Hum Genet       Date:  1972-05       Impact factor: 11.025

Review 7.  Toward enzyme therapy for lysosomal storage diseases.

Authors:  R J Desnick; S R Thorpe; M B Fiddler
Journal:  Physiol Rev       Date:  1976-01       Impact factor: 37.312

8.  Purification and properties of human alpha-galactosidases.

Authors:  E Beutler; W Kuhl
Journal:  J Biol Chem       Date:  1972-11-25       Impact factor: 5.157

9.  Biochemical and electrophoretic studies of -galactosidase in normal man, in patients with Fabry's disease, and in Equidae.

Authors:  E Beutler; W Kuhl
Journal:  Am J Hum Genet       Date:  1972-05       Impact factor: 11.025

10.  Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts.

Authors:  A Kaplan; D T Achord; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

View more
  8 in total

1.  Carpal tunnel syndrome in fabry disease.

Authors:  Joanna Ghali; Anand Murugasu; Timothy Day; Kathy Nicholls
Journal:  JIMD Rep       Date:  2011-09-06

2.  Preselective gene therapy for Fabry disease.

Authors:  G Qin; T Takenaka; K Telsch; L Kelley; T Howard; T Levade; R Deans; B H Howard; H L Malech; R O Brady; J A Medin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.

Authors:  T Ohshima; R Schiffmann; G J Murray; J Kopp; J M Quirk; S Stahl; C C Chan; P Zerfas; J H Tao-Cheng; J M Ward; R O Brady; A B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

4.  A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.

Authors:  Yo Kyung Chung; Young Bae Sohn; Jong Mun Sohn; Jieun Lee; Mi Sun Chang; Younghee Kwun; Chi Hwa Kim; Jin Young Lee; Yeon Joo Yook; Ah-Ra Ko; Dong-Kyu Jin
Journal:  Glycoconj J       Date:  2014-04-30       Impact factor: 2.916

5.  Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.

Authors:  Ester M Pereira; Anatália Labilloy; Megan L Eshbach; Ankita Roy; Arohan R Subramanya; Semiramis Monte; Guillaume Labilloy; Ora A Weisz
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-28

6.  Loss of electron-dense lamellar material from Fabry's disease fibroblasts after enzyme replacement.

Authors:  R N Sifers; J S Mayes; R E Nordquist
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

7.  Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice.

Authors:  Su Xu; Yi Lun; Nastry Brignol; Rick Hamler; Adriane Schilling; Michelle Frascella; Sean Sullivan; Robert E Boyd; Kate Chang; Rebecca Soska; Anadina Garcia; Jessie Feng; Hidehito Yasukawa; Carole Shardlow; Alison Churchill; Amol Ketkar; Nicola Robertson; Masahito Miyamoto; Kazutoshi Mihara; Elfrida R Benjamin; David J Lockhart; Tohru Hirato; Susie Fowles; Kenneth J Valenzano; Richie Khanna
Journal:  Mol Ther       Date:  2015-04-27       Impact factor: 11.454

8.  Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study.

Authors:  Dominique P Germain; Eva Brand; Alessandro Burlina; Franco Cecchi; Scott C Garman; Judy Kempf; Dawn A Laney; Aleš Linhart; László Maródi; Kathy Nicholls; Alberto Ortiz; Federico Pieruzzi; Suma P Shankar; Stephen Waldek; Christoph Wanner; Ana Jovanovic
Journal:  Mol Genet Genomic Med       Date:  2018-04-12       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.